Kyuri Kang

Mrs. Kyuri Kang

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 September 2023 in Journal of Medical Virology
Verified
Journal Article
Closed access
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
KKKyuri Kang
Kyuri Kang
YKYe Ji Kim
Ye Ji Kim
JKJin-Han Kang
Jin-Han Kang
Soo-Young LeeSoo-Young Lee
Soo-Young Lee

1 January 2015 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
SHSeung Beom Han
Seung Beom Han
KKKyuri Kang
Kyuri Kang
DHDong Ho Huh
Dong Ho Huh
HLHee Chul Lee
Hee Chul Lee
Soo-Young LeeSoo-Young Lee
Soo-Young Lee
JKJin-Han Kang
Jin-Han Kang
Han SB, et al. Clin Exp Vaccine Res. 2015 Jan;4(1):75-82. https://doi.org/10.7774/cevr.2015.4.1.75

1 January 2019 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
CPChulmin Park
Chulmin Park
DHDong Ho Huh
Dong Ho Huh
SHSeung Beom Han
Seung Beom Han
GCGi Sub Choi
Gi Sub Choi
KKKyuri Kang
Kyuri Kang
JKJin-Han Kang
Jin-Han Kang
Park C, et al. Clin Exp Vaccine Res. 2019 Jan;8(1):35-42. https://doi.org/10.7774/cevr.2019.8.1.35

1 January 2019 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
GCGi Sub Choi
Gi Sub Choi
DHDong Ho Huh
Dong Ho Huh
SHSeung Beom Han
Seung Beom Han
DADong Ho Ahn
Dong Ho Ahn
KKKyuri Kang
Kyuri Kang
JKJin-Han Kang
Jin-Han Kang
Choi GS, et al. Clin Exp Vaccine Res. 2019 Jan;8(1):64-69. https://doi.org/10.7774/cevr.2019.8.1.64

5 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
BABin Ahn
Bin Ahn
KKKyuri Kang
Kyuri Kang
YKYe Ji Kim
Ye Ji Kim
YCYoon Kyung Cho
Yoon Kyung Cho
SJSuejung Jo
Suejung Jo
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy. Additionally, it sought to compare fluorescent-antibody-to-membrane-antigen (FAMA) and enzyme-linked immunosorbent assay (ELISA) titers to establish effective cut-off levels for protection against varicella. Methods: The FAMA assay was conducted at the Vaccine Bio Research Institute, and a VARICELLA-ZOSTER ELISA (Vircell, Granada, Spain) kit, which relies on lysate from whole cells infected with VZV, was used to determine VZV IgG. A prospective cohort study was conducted with 76 pediatric patients under 18 years old who tested negative for VZV IgG via ELISA. Patients post-HSCT and post-chemotherapy were included. Participants received the MAV/06 varicella vaccine, and serologic responses were evaluated using ELISA and FAMA. Results: The median age of participants was 9.8 years, with acute lymphoid leukemia and acute myeloid leukemia being the most common underlying disease. Post-dose 1, the seropositive rate was 56.1% by ELISA and 97.2% by FAMA. Based on the FAMA seropositive cut-off ≥1:4, post-dose 1 geometric mean titers (GMTs) of seropositive patients in the post-HSCT group were 14.7 (95% CI, 11.3–19.1) versus 20.2 (95% CI, 13.0–31.3) in the post-chemotherapy group (p = 0.690). Based on a FAMA seropositive cut-off ≥1:16, the post-dose 1 GMT of patients considered seropositive in the post-HSCT group was 19.3 (95% CI, 15.6–24.0) versus 34.1 (95% CI, 21.0–55.4) in the post-chemotherapy group (p = 0.116), and post-dose 2 FAMA titers of 76.1 (95% CI, 14.6–398.1) in the post-HSCT group and 64.0 (95% CI, 11.4–358.1) in the post-HSCT group (p = 0.853) were observed. In patients with lower baseline FAMA titers (1:4 to 1:8), 66.7% in the post-HSCT group and 71.5% in the post-chemotherapy group achieved a greater than four-fold increase in FAMA titers post-dose 1, while those with higher baseline titers (≥1:16) did not. There were no serious adverse events or vaccine-related rashes occurring in any of the patients. Conclusion: The MAV/06 varicella vaccine is immunogenic in pediatric patients post-HSCT and post-chemotherapy, particularly when administered in a two-dose schedule using a cut-off FAMA titer of <1:16.

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
TSThomas Söderhäll
Thomas Söderhäll
SKSeung-Bum Kim
Seung-Bum Kim
GCGi-Sub Choi
Gi-Sub Choi
KKKyuri Kang
Kyuri Kang
JJJoon-Hwan Ji
Joon-Hwan Ji
JKJin-Han Kang
Jin-Han Kang
Söderhäll T, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):338-347. https://doi.org/10.7774/cevr.2024.13.4.338